



Notes to Editors:-

1. Tri-Air Developments Ltd has invented and patented decontamination technology to destroy airborne and surface bacteria and viruses within minutes. This ranges from the common cold and flu, to MRSA and other HAI (Hospital Acquired Infections) - as well as Norovirus, H1N1 Swine Flu, H5N1 Bird Flu, and CBRN bio-terrorism threats.
2. Advantages: the speed and range of protection from pathogenic viruses and bacteria, with decontamination occurring in the air and on surfaces. It is an estimated 100 times more powerful than other methods of decontamination.
3. The air-purification process: the Tri-Air technology creates a continual supply of hydroxyl radicals – a 'fresh air' effect - dispersed throughout a room. It is not a filtration process: decontamination occurs both within and outside the machine, without the need to process all of the air through the unit.
4. Technology: it is patented in 36 jurisdictions and combines three methods of decontamination in a single process: **non-thermal plasma** generates ozone, destroys unwanted particulates, creates hydroxyl radicals and prevents surface fouling; **ultraviolet catalysis** further removes unwanted contaminants and increases hydroxyl radicals; **residual ozone** blended with Tri-Air terpene mixes to create and emit hydroxyl radicals
5. Evidence: Tests on Tri-Air devices show kill rates to 99.9999% for airborne test virus MS2 Coliphage in under 5 minutes; 99.999% of airborne Staphylococcus epidermis within 2 minutes; and 99.9999% of surface MRSA on glass over a 24-hour period. Source: UK HPA (Health Protection Agency), Centre for Emergency Preparedness & Response:
6. Production: the technology is scalable from a personal device that can be worn, to a stand-alone unit to safeguard a room, and full integration in ventilation systems. The technology can be tuned for constant low-level background protection, such as in a home or hospital, up to a 'fail-safe' setting for a Cat.4 secure facility for homeland security.
7. Applications: medical, to protect hospitals from MRSA and other HAI (Hospital Acquired Infections); commercial and domestic applications to guard against colds and flu; homeland security, to counter CBRN biological terror weapons; and food processing plants, for improved hygiene.
8. Safety: the technology is completely safe. It creates some of the active components of fresh air, which renders viruses harmless, but in such a way that the body's immune reaction is still triggered - thereby creating a further safeguard against the spread of disease.
9. Current Users: Tri-Air Developments is licensing the technology to exclusive suppliers in selected markets. The first licensee is BA Holdings (March 2010), which has marketed 'fragrance delivery' systems to the premium leisure sector since 2004. The system will protect patrons of hotels, casinos and cruise liners.
10. The company: it is registered in the UK, co-founded by the UK's BRE (Building Research Establishment), microbiologists at Promanade Ltd and technology transfer specialists Inventa Partners Ltd.
11. CEO comment: "Tri-Air is now licensing the technology to manufacturers, integrators and other service companies supplying the armed forces, airports, shopping malls, Government buildings, offices and domestic markets worldwide. The system offers protection for security and civilian staff, visiting clients and general public, from viruses, bacteria and bio-attack - even from the common cold," says Gideon Davenport, CEO of Tri-Air Developments.

Media information:-

Patrick.Rea@rea-tma.co.uk

Tel +44 020 8870 4976

Further information:-

www.tri-airdevelopments.com

Tri-Air Developments Ltd, Building 01/005, Bucknalls Lane, Watford, WD25 9XX

Tel: +44 (0) 1923 – 665213

info@tri-airdevelopments.com